Pfizer Inc. picked up rights to biosimilar versions of insulin in a potential $350 million-plus partnership with Indian biotech Biocon Ltd. that gives the big pharma firm access to the multibillion-dollar insulin space, as well as immediate inroads to emerging markets. (BioWorld Today)